% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hertler:276424,
      author       = {C. Hertler and J. Felsberg and D. Gramatzki and E. Le Rhun
                      and J. Clarke and R. Soffietti and W. Wick$^*$ and O. Chinot
                      and F. Ducray and P. Roth and K. McDonald and P. Hau and A.
                      F. Hottinger and J. Reijneveld and O. Schnell and C. Marosi
                      and M. Glantz and A. Darlix and G. Lombardi and D. Krex$^*$
                      and M. Glas$^*$ and D. A. Reardon and M. van den Bent and F.
                      Lefranc and U. Herrlinger and E. Razis and A. F. Carpentier
                      and S. Phillips and R. Rudà and A. Wick and E. Tabouret and
                      D. Meyronet and C.-A. Maurage and E. Rushing and R. Rapkins
                      and E. Bumes and M. Hegi and A. Weyerbrock and D. Aregawi
                      and C. Gonzalez-Gomez and A. Pellerino and M. Klein and M.
                      Preusser and M. Bendszus and V. Golfinopoulos and A. von
                      Deimling$^*$ and T. Gorlia and P. Y. Wen and G.
                      Reifenberger$^*$ and M. Weller},
      title        = {{L}ong-term survival with {IDH} wildtype glioblastoma:
                      first results from the {ETERNITY} {B}rain {T}umor {F}unders'
                      {C}ollaborative {C}onsortium ({EORTC} 1419).},
      journal      = {European journal of cancer},
      volume       = {189},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01107},
      pages        = {112913},
      year         = {2023},
      note         = {Volume 189, August 2023, 112913},
      abstract     = {Median survival with glioblastoma remains in the range of
                      12 months on population levels. Only few patients survive
                      for more than 5 years. Patient and disease features
                      associated with long-term survival remain poorly
                      defined.European Organization for Research and Treatment of
                      Cancer (EORTC) 1419 (ETERNITY) is a registry study supported
                      by the Brain Tumor Funders Collaborative in the US and the
                      EORTC Brain Tumor Group. Patients with glioblastoma
                      surviving at least 5 years from diagnosis were identified at
                      24 sites in Europe, US, and Australia. In patients with
                      isocitrate dehydrogenase (IDH) wildtype tumours, prognostic
                      factors were analysed using the Kaplan-Meier method and the
                      Cox proportional hazards model. A population-based reference
                      cohort was obtained from the Cantonal cancer registry
                      Zurich.At the database lock of July 2020, 280 patients with
                      histologically centrally confirmed glioblastoma (189 IDH
                      wildtype, 80 IDH mutant, 11 incompletely characterised) had
                      been registered. In the IDH wildtype population, median age
                      was 56 years (range 24-78 years), 96 patients $(50.8\%)$
                      were female, 139 patients $(74.3\%)$ had tumours with
                      O6-methylguanine DNA methyltransferase (MGMT) promoter
                      methylation. Median overall survival was 9.9 years $(95\%$
                      confidence interval $[95\%$ CI] 7.9-11.9). Patients without
                      recurrence experienced longer median survival (not reached)
                      than patients with one or more recurrences (8.92 years) (p <
                      0.001) and had a high rate $(48.8\%)$ of MGMT
                      promoter-unmethylated tumours.Freedom from progression is a
                      powerful predictor of overall survival in long-term
                      survivors with glioblastoma. Patients without relapse often
                      have MGMT promoter-unmethylated glioblastoma and may
                      represent a distinct subtype of glioblastoma.},
      keywords     = {IDH (Other) / MGMT (Other) / Outcome (Other) / Prognosis
                      (Other) / Registry (Other) / Wildtype (Other)},
      cin          = {B320 / B300 / DD01 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)B320-20160331 / I:(DE-He78)B300-20160331 /
                      I:(DE-He78)DD01-20160331 / I:(DE-He78)ED01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37277265},
      doi          = {10.1016/j.ejca.2023.05.002},
      url          = {https://inrepo02.dkfz.de/record/276424},
}